First author | Year | Country | Subjectsa | Mutation detection rate | Germline mutation | Clinical risk suggestion | |
---|---|---|---|---|---|---|---|
Site | Type | ||||||
Wang [17] | 2014 | China | 35 | 67.3% | Exon 7 | – | High incidence of GI polyp dysplasia |
van Lier [4] | 2011 | Netherlands | 77 | 96.3% | – | – | Independent of STK11 mutation status |
Mehenni [18] | 2007 | Switzerland | 27 | 28.7% | – | – | No significant influence |
Mehenni [19] | 2006 | EU, AS | 40 | 26.8% | Exon 6 | – | Higher risk of cancer |
Hearle [20] | 2006 | EU, AU, US | 297 | 70.9% | – | – | No significant influence |
Schumacher [21] | 2005 | b | 132 | – | Exon 1-7 - Exon 4-5 | Deletion Splice site Missense | Rarely associated with cancer Significantly associated with cancer Associated with malignancies |
Lim [22] | 2004 | EU, AU, US | 78 | 32.5% | Exon 3 | – | Higher cancer risk |